Harada Chikako, Noro Takahiko, Kimura Atsuko, Guo Xiaoli, Namekata Kazuhiko, Nakano Tadashi, Harada Takayuki
Visual Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.
Department of Ophthalmology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.
Antioxidants (Basel). 2020 Sep 16;9(9):874. doi: 10.3390/antiox9090874.
Glaucoma is a neurodegenerative disease of the eye, which involves degeneration of retinal ganglion cells (RGCs): the output neurons of the retina to the brain, which with their axons comprise the optic nerve. Recent studies have shown the possible involvement of oxidative stress in the pathogenesis of glaucoma, especially in the subtype of normal tension glaucoma. Basic experiments utilizing rodent and primate models of glaucoma revealed that antioxidants protect RGCs under various pathological conditions including glutamate neurotoxicity and optic nerve injury. These results suggested that existing drugs and food factors may be useful for prevention and hence therapy of glaucoma. In this review, we highlight some therapeutic candidates, particularly those with antioxidant properties, and discuss the therapeutic potential of RGC protection by modulating gene expressions that prevent and ameliorate glaucoma.
青光眼是一种眼部神经退行性疾病,涉及视网膜神经节细胞(RGCs)的退化:视网膜向大脑输出信号的神经元,其轴突构成视神经。最近的研究表明氧化应激可能参与青光眼的发病机制,尤其是在正常眼压性青光眼亚型中。利用青光眼啮齿动物模型和灵长类动物模型进行的基础实验表明,抗氧化剂在包括谷氨酸神经毒性和视神经损伤在内的各种病理条件下可保护RGCs。这些结果表明现有药物和食物因子可能对青光眼的预防及治疗有用。在这篇综述中,我们重点介绍了一些治疗候选物,特别是那些具有抗氧化特性的候选物,并讨论了通过调节预防和改善青光眼的基因表达来保护RGCs的治疗潜力。